Human VEGF R2/KDR Protein

Cat. No. VGF-HM3R2

Description

Source	Recombinant Human VEGF R2/KDR Protein is expressed from HEK293 with mFc (IgG1) tag at the C-Terminus.
	It contains Ala20-Glu764.
Accession	P35968-1
Molecular Weight	The protein has a predicted MW of 110 kDa. Due to glycosylation, the protein migrates to 150-200 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage

Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. The tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of angiogenesis.

Assay Data

Bis-Tris PAGE



Human VEGF R2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human VEGF R2 is greater than 95% as determined by SEC-HPLC.

Human VEGF R2/KDR Protein

Cat. No. VGF-HM3R2

Assay Data

ELISA Data



Immobilized Human VEGF165 at 1μg/ml (100μl/Well) on the plate. Dose response curve for Human VEGF R2, mFc Tag with the EC50 of 42.3ng/ml determined by ELISA.